AzTrials
AzTrials

ScabiesEarly Phase 1NCT07247630

Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children

A Early Phase 1 study testing Permethrin 5% in people with Scabies, run by College of Physicians and Surgeons Pakistan at 1 site in Pakistan.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

To compare the efficacy of different permethrin-based therapies for scabies infestations in infants and young children. Read more about this study

Who is it for?
Ages 1 month to 4 years
Conditions the study is for
Scabies
What is being tested?
Permethrin 5%
Could I receive a placebo?
No, everyone receives an active treatment
How many people
68 participants
Where
1 sitePakistan
Study dates
15 Jan 2026to 15 Jun 2026
Phase
Early Phase 1

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 4 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • 1 month to 4 years age.
  • Both gender
  • Scabies as defined in operational definition

Who cannot join

  • • Drug sensitivity test results for hypersensitivity to permethrin
  • Having renal or hepatic impairment.
  • Individuals with additional long-term skin and systemic disorders (such as diabetes, hypertension, asthma, epilepsy, acne, psoriasis)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Shanza zafar, MBBs contact

+923425316096

shanza444@gmail.com

Pakistan1 site
  • Pak emirates military hospital,Rawalpindi

    Rawalpindi, Punjab Province, 00666

Other trials in Pakistan

About this study

To compare the efficacy of different permethrin-based therapies for scabies infestations in infants and young children.

Read the detailed description

Globally, Scabies infects 300 million people each year and among children of developing countries, its prevalence is estimated to be about 5-10%.In Pakistan, Scabies accounts for 38% of dermatological diseases. Males are more prone to infestation than females, and early school- aged children are the most vulnerable as it is usually transmitted by prolonged skin-skin contact.

It was more widespread in urban than in rural areas with a distinct seasonal pattern, with the biggest infestation occurring in the winter and the lowest in the summer with all risk factors accounting for 89% of the variation in its prevalence.The classic scabies symptoms include an erythematous papular eruption, burrows, and intense itching with a predilection for fingers, axilla, elbows, waist, belly, groin, genital area, etc. Several antiscabietic treatment options exist, including topically applied permethrin, benzyl benzoate (BB) and crotamiton, and oral ivermectin.5 Repeated administration of topical permethrin 5%, topical BB 10-25% or systemic ivermectin dosed at 200 μg/kg body weight is currently recommended as first-line treatment by the 2017 European guidelines for the management of scabies.Permethrin, a synthetic pyrethroid with scabicidal and ovicidal activity, disrupts the function of the voltage-gated sodium channels in the neuronal membrane of the mites, resulting in paralysis and death. Permethrin is highly effective against scabies and well- tolerated without major side-effects, as it is minimally absorbed through the skin and rapidly eliminated, thus exerting minimal systemic presence in humans.Hence, it is recommended as a first-line therapy for adults and children in many countries

Conditions
Scabies
Being tested
Permethrin 5%
Keywords
Permethrin based treatment strategies
Medical subject headings
Scabies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Permethrin 5%Drug

    permethrin application

Study groups in NCT07247630
Study groupRoleWhat they receive
Standard permethrin treatmentActive comparatorStandard permethrin treatment
Receives: Drug: Permethrin 5%
Intensified permethrin treatmentActive comparatorIntensified permethrin treatment
Receives: Drug: Permethrin 5%

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Treatment of scabies

    For efficacy, we will see microscopy (presence of any one by examine skin scraping under a microscope for mites(eyeless and spherical in shape with eight legs parasite)/eggs (oval shape).The absence of these will be considered significant.

    Measured: 15 days

Secondary outcomes (2)
  1. Scabies

    Absence of burrows on skin

    Measured: 15 days

  2. Scabies

    Absence of pruritus

    Measured: 15 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Nov 2025
  2. Study start15 Jan 2026 (estimated)
  3. Primary completion15 Mar 2026 (estimated)
  4. Study completion15 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
68 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07247630
Sponsor's protocol ID
A/28/ERC.63.25
Status last verified
Feb 2026
First submitted
1 Oct 2025
Last updated
3 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in